Mayo Clinic prepared to commenced phase II FDA clinical trial for treatment of COVID-19 with Vicromax
On Apr. 16, 2020, BioSig Technologies announced that its subsidiary ViralClear Pharmaceuticals, had updated its clinical development program…
On Apr. 16, 2020, BioSig Technologies announced that its subsidiary ViralClear Pharmaceuticals, had updated its clinical development program…
On Apr. 15, 2020, HALIX announced it had joined a consortium of partners under the guidance of the…
On Apr. 15, 2020, Humanigen announced that U.S. Food and Drug Administration (FDA) had given permission to commence…
On Apr. 15, 2020, Vanda Pharma and Northwell Health’s research arm, The Feinstein Institutes for Medical Research, announced…
On Apr. 15, 2020, Bellicum Pharma announced closing of the sale of its Houston facility to The University…
On Apr. 14, 2020, AstraZeneca initiated a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib)…
On Apr. 14, 2020, Sinovac Biotech announced that the Company had obtained approval to conduct a human clinical…
On Apr. 14, 2020, NantKwest and ImmunityBio announced discussions with the FDA for vaccines and therapeutics to combat…
On Apr. 13, 2020, Bausch Health announced it has initiated a clinical trial program in Canada evaluating an…
On Apr. 10, 2020, BenevolentAI announced that baricitinib, which it had identified as a potential treatment for COVID-19,…
On Apr. 9, 2020, the first participants were enrolled in the trial at Vanderbilt University Medical Center, Nashville,…
On Apr. 9, 2020, FUJIFILM announced initiation of a U.S. phase II clinical trial to evaluate the safety…
On Apr. 9, 2020, Laurent Pharmaceuticals announced that a spin off from McGill University planned to test its…
On Apr. 9, 2020, BioSig Technologies announced that an article titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications”…
On Apr. 9, 2020, Washington University School of Medicine in St. Louis launched a clinical trial for patients…
On Apr. 9, 2020, BioCryst Pharmaceuticals announced the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical…
On Apr. 9, 2020, iBio announced the signing of two agreements with the Infectious Disease Research Institute (IDRI)…
On Apr. 9, 2020, CytoDyn announced a patient with severe COVID-19 under the care of a leading medical…
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
On Apr. 8, 2020, MediciNova announced that it had initiated a clinical trial of MN-166 (ibudilast) for acute…
On Apr. 7, 2020, Karyopharm Therapeutics announced plans to initiate a global randomized clinical trial for low dose…
On Apr. 6, 2020, OncoSec Medical announced that Providence Cancer Institute, a part of Providence St. Joseph Health…
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
On Apr. 6, 2020, AIM ImmunoTech announced a Material Transfer and Research Agreement (MTA) with Shenzhen Smoore Technology…
On Apr. 6, 2020, Emory’s Vaccine and Treatment Evaluation Unit (VTEU) announced its participation in a clinical trial…
On Apr. 4, 2020, Mesa Biotech announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza…
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
On Apr. 2, 2020, Incyte announced it was working with the U.S. Food and Drug Administration (FDA) to…
On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe…
On Apr. 2, 2020, Roswell Park Comprehensive Cancer Center and the University at Buffalo (UB) launched a collaborative…